Results about: Inbiomotion

Roger Gomis: heading from the lab to the market

ICREA researcher Roger Gomis, head of the Growth Control and Cancer Metastasis Lab, has recently been awarded a 2016 "Knowledge Industry Grant" (Producte), by the Catalan Government’s Agency for Management of University and Research Grants, for the further development of a therapy for the treatment of breast cancer. His 18-month project, "Lipid targeting in breast cancer", aims to obtain a monoclonal antibody, based on a well-defined molecular target, that is suitable for patient treatment and to complete its pre-clinical development phase. 

An international consortium identifies the breast cancer patients who would benefit from a treatment to prevent metastasis

A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.

This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.

Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.

”la Caixa” leads an investment round in IRB Barcelona's spin off Inbiomotion

The company concludes a 2.2 million € round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital and Fundación Vila Casas.

Inbiomotion, a spin off founded by IRB Barcelona's group leader, Roger Gomis,  develops diagnostic products for predicting risks that cancer patients may suffer bone metastasis.